PER Stock Overview
Engages in the research and development of novel antisense pharmaceuticals in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Percheron Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.007 |
| 52 Week High | AU$0.14 |
| 52 Week Low | AU$0.005 |
| Beta | 0.90 |
| 1 Month Change | -90.54% |
| 3 Month Change | -93.00% |
| 1 Year Change | -87.27% |
| 3 Year Change | -96.50% |
| 5 Year Change | -92.05% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully
Jun 03
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Nov 13We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate
Jun 08We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
Feb 14We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely
Aug 26Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation
May 12We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Dec 23Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation
Jun 24We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
Mar 11Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?
Nov 26
Shareholder Returns
| PER | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -88.1% | -4.9% | -2.7% |
| 1Y | -87.3% | -9.3% | 6.5% |
Return vs Industry: PER underperformed the Australian Pharmaceuticals industry which returned -9.3% over the past year.
Return vs Market: PER underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility
| PER volatility | |
|---|---|
| PER Average Weekly Movement | 28.5% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: PER's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: PER's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | James Garner | www.PercheronTx.com |
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
Percheron Therapeutics Limited Fundamentals Summary
| PER fundamental statistics | |
|---|---|
| Market cap | AU$7.42m |
| Earnings (TTM) | -AU$11.92m |
| Revenue (TTM) | AU$2.97m |
2.5x
P/S Ratio-0.6x
P/E RatioIs PER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PER income statement (TTM) | |
|---|---|
| Revenue | AU$2.97m |
| Cost of Revenue | AU$62.15k |
| Gross Profit | AU$2.91m |
| Other Expenses | AU$14.83m |
| Earnings | -AU$11.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 97.91% |
| Net Profit Margin | -401.57% |
| Debt/Equity Ratio | 0% |
How did PER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:37 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Iain Wilkie | Morgans Financial Limited |
| Dr Storey | Wilsons Advisory and Stockbroking Ltd. |